IDEAS home Printed from https://ideas.repec.org/a/lrk/eeaart/31_2_14.html
   My bibliography  Save this article

Nuevas perspectivas sobre el precio de los medicamentos: El caso español/New Perspectives on Drug Pricing: The Spanish Case

Author

Listed:
  • CABIEDES MIRAGAYA, LAURA

    () (Universidad de Oviedo, Facultad de Economía y Empresa, Campus del Cristo, Avda. del Cristo, s/n, 33006 Oviedo, España.)

Abstract

La mayoría de los países de nuestro entorno socioeconómico regula el precio de los medicamentos nuevos (protegi¬dos por una patente), sobremanera si son objeto de financiación con fondos públicos. Pese a existir razones teóricas y por tanto argumentos compartidos, las formas de intervención pueden diferir notablemente entre países y en el tiempo. De hecho, el centro de atención se ha ido desplazando del flanco de los costes (perspectiva del productor) al flanco del valor (perspectiva del usuario/sociedad). Con apoyo en la legislación y en la escasa evidencia empírica disponible, se concluyó que en España la intervención no responde al nuevo enfoque del precio basado en el valor terapéutico aportado por el medicamento frente a las alternativas disponibles. Asimismo, el caso español fue objeto de comparación con Estados Unidos y Suecia. Most developed countries regulate prices for on-patent drugs, especially if they are publicly funded. Although theoretical reasons -and therefore shared justifications- exist to intervene, pricing schemes may differ considerably from one country to another, as well as in the course of time. In fact, the current focus has been shifting away from cost considerations (the manufacturer´s perspective) towards value considerations (the user/society perspective). With the support of the current legislation and the scarce empirical evidence available to date, it was concluded that in Spain the intervention does not respond to a value-based pricing approach, namely, the prices of new drugs do not reflect their therapeutic value relative to existing alternatives. Besides, the Spanish case was compared with Sweden and the United States.

Suggested Citation

  • Cabiedes Miragaya, Laura, 2013. "Nuevas perspectivas sobre el precio de los medicamentos: El caso español/New Perspectives on Drug Pricing: The Spanish Case," Estudios de Economía Aplicada, Estudios de Economía Aplicada, vol. 31, pages 397-416, Septiembr.
  • Handle: RePEc:lrk:eeaart:31_2_14
    as

    Download full text from publisher

    File URL: http://www.revista-eea.net
    Download Restriction: Access to full text is restricted to subscribers.

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Z. John Lu & William S. Comanor, 1998. "Strategic Pricing Of New Pharmaceuticals," The Review of Economics and Statistics, MIT Press, vol. 80(1), pages 108-118, February.
    2. Dean, Joel, 1969. "Pricing Pioneering Products," Journal of Industrial Economics, Wiley Blackwell, vol. 17(3), pages 165-179, July.
    3. Mats Ekelund & Björn Persson, 2003. "Pharmaceutical Pricing in a Regulated Market," The Review of Economics and Statistics, MIT Press, vol. 85(2), pages 298-306, May.
    Full references (including those not matched with items on IDEAS)

    More about this item

    Keywords

    Nuevos principios activos; innovación terapéutica; regulación del precio de los medicamentos; precio basado en el valor ; New Chemical Entities; Therapeutic Innovation; Pharmaceutical Price Regulation; Value-Based Pricing .;

    JEL classification:

    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
    • H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health
    • L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
    • L51 - Industrial Organization - - Regulation and Industrial Policy - - - Economics of Regulation

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:lrk:eeaart:31_2_14. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Beatriz Rodríguez Prado). General contact details of provider: http://edirc.repec.org/data/fcvldes.html .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.